UCB Pharma (division of UCB Australia Pty Ltd)

Regulatory activities for this sponsor.

2 result(s) found, displaying 1 to 2

Bimzelx

7 April 2022

Prescription medicine decision summary

TGA Decision: Bimzelx (bimekizumab) is approved to treat moderate to severe plaque psoriasis in adult patients.
BIMZELX (UCB Pharma (division of UCB Australia Pty Ltd))

17 March 2022

Prescription medicine registration

Active ingredients: bimekizumab.